Aligos Therapeutics, INC Form 4 insider transactions

Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, reported the acquisition of stock options on March 1, 2024.

Aligos Therapeutics CEO Lawrence Blatt reports acquisition of stock options in the company.

Director Peter Hirth participated in Aligos Therapeutics' option exchange program, canceling an existing option and receiving a replacement option with a lower exercise price.

Director James Scopa participated in Aligos Therapeutics' option exchange program, canceling an existing option and receiving a replacement option with a lower exercise price.

Chief Medical Officer Matthew W. McClure participated in Aligos Therapeutics' option exchange program, resulting in the cancellation of existing stock options and the grant of new options with a different exercise price.

Lesley Ann Calhoun, CFO of Aligos Therapeutics, participated in the company's option exchange program, resulting in the cancellation of existing stock options and the grant of new replacement options.

Aligos Therapeutics CEO Lawrence Blatt participated in an option exchange program, canceling existing stock options and receiving new replacement options with a different exercise price and vesting schedule.

Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Julian A. Symons, participated in an option exchange program, resulting in the cancellation of existing stock options and the grant of new options with a different exercise price.

Director Jack Nielsen participated in Aligos Therapeutics' option exchange program, canceling an existing option and receiving a replacement option with a lower exercise price.

Director Carole Nuechterlein exchanged stock options in Aligos Therapeutics, canceling an existing option for 15,000 shares and receiving a replacement option for 4,411 shares with a lower exercise price.

Director Bridget Martell exchanged stock options in Aligos Therapeutics, canceling an option for 30,000 shares and receiving a replacement option for 8,823 shares.